List view / Grid view
30 June 2016 | By Victoria White, Digital Content Producer
While the study did not meet its primary endpoint of reducing severity of ROP, it did produce encouraging secondary endpoints related to lung and brain...
30 June 2016 | By Victoria White, Digital Content Producer
Orexo’s Zubsolv (buprenorphine and naloxone sublingual tablet) is a potential new treatment option for patients with opioid dependence...
30 June 2016 | By Victoria White, Digital Content Producer
In the statement, EFPIA underscores the importance of ensuring that the patient is at the centre of all subsequent decisions...
30 June 2016 | By Victoria White, Digital Content Producer
INMARK is a study investigating the effect of Ofev (nintedanib) on changes in specific blood biomarkers in patients with idiopathic pulmonary fibrosis...
30 June 2016 | By Victoria White, Digital Content Producer
ImmBio has reported positive results from the First-in-Human study of its novel vaccine, PnuBioVax, against the bacterial pathogen Streptococcus pneumoniae...
29 June 2016 | By Victoria White, Digital Content Producer
GlobalData says MenABCWY has the potential to significantly change the approach used to prevent meningococcal disease...
29 June 2016 | By Victoria White, Digital Content Producer
Results from the Phase III RESORCE trial investigating Bayer’s regorafenib in patients with unresectable hepatocellular carcinoma have been announced...
29 June 2016 | By Victoria White, Digital Content Producer
Epclusa is the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection...
29 June 2016 | By Victoria White, Digital Content Producer
Findings from the largest global survey to date of people with psoriasis reveal 84% of people with moderate-to-severe psoriasis suffer discrimination...
28 June 2016 | By Victoria White, Digital Content Producer
A study has found that controversy over the risks and benefits of statins was followed by an increase in people stopping their statin treatment...
28 June 2016 | By Victoria White, Digital Content Producer
Two Phase III trials of Pfizer’s bococizumab, SPIRE-HR (HighRisk) and SPIRE-FH (Familial Hypercholesterolemia), met their primary endpoint...
28 June 2016 | By Victoria White, Digital Content Producer
Pfizer is to invest $350 million in the development of a state-of-the-art Global Biotechnology Centre in the Hangzhou Economic Development Area...
28 June 2016 | By Victoria White, Digital Content Producer
Celyad has announced headline results for CHART-1, its European Phase III clinical trial for its lead cardiovascular disease product candidate - C-Cure...
28 June 2016 | By Victoria White, Digital Content Producer
If approved by the EMA and FDA for both indications, Ocrevus would be the first and only treatment for both forms of multiple sclerosis...
28 June 2016 | By Victoria White, Digital Content Producer
The collaboration includes XmAb Bispecific Technology for 4 Novartis targets and access to Xencor Fc Technologies...
